Sfmg LLC Lowers Stake in AbbVie Inc. $ABBV

Sfmg LLC lessened its position in AbbVie Inc. (NYSE:ABBV) by 12.7% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,651 shares of the company’s stock after selling 823 shares during the period. Sfmg LLC’s holdings in AbbVie were worth $1,049,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC boosted its stake in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the last quarter. Revolve Wealth Partners LLC lifted its holdings in shares of AbbVie by 72.7% during the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. Machina Capital S.A.S. purchased a new position in shares of AbbVie during the 1st quarter worth about $799,000. Brookwood Investment Group LLC acquired a new stake in shares of AbbVie in the first quarter worth approximately $722,000. Finally, Avantax Advisory Services Inc. grew its holdings in AbbVie by 2.3% in the first quarter. Avantax Advisory Services Inc. now owns 219,941 shares of the company’s stock valued at $46,082,000 after purchasing an additional 4,912 shares during the period. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. DZ Bank lowered AbbVie from a “buy” rating to a “hold” rating and set a $237.00 target price on the stock. in a research report on Tuesday, November 4th. Piper Sandler reiterated an “overweight” rating and issued a $289.00 target price (up previously from $284.00) on shares of AbbVie in a report on Wednesday, November 5th. BMO Capital Markets upped their price target on AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research note on Friday, September 12th. Finally, Wall Street Zen upgraded AbbVie from a “buy” rating to a “strong-buy” rating in a report on Saturday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, AbbVie currently has an average rating of “Moderate Buy” and an average price target of $241.85.

AbbVie Trading Up 2.9%

NYSE:ABBV opened at $236.12 on Friday. The business’s 50-day moving average is $226.81 and its two-hundred day moving average is $205.22. The firm has a market capitalization of $417.31 billion, a PE ratio of 112.44, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The company’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter last year, the firm earned $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Research analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a dividend of $1.73 per share. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is 524.24%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.